30-Mar-2026 8:34 AM CST - Yahoo Finance How Investors May Respond To Merck (MRK) WINREVAIR Phase 2 Success In Tough Heart Failure Segment Earlier this week, Merck & Co., Inc. reported detailed Phase 2 CADENCE results showing WINREVAIR (sotatercept-csrk) significantly reduced pulmonary vascular resistance in adults with combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction,
29-Mar-2026 8:05 AM CST - Seeking Alpha Notable healthcare headlines for the week: Merck, Medtronic, and Novartis in focus Under the terms of the merger agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Terns. As a result of the IPO, the company projects a total dilutive effect of $0.04 per share for Q4 fiscal 2026,
27-Mar-2026 12:08 PM CST - Yahoo Finance Merck Stock Soars 50% in 6 Months: Buy, Hold, or Take Profits? MRK stock has surged over 50% in six months, but looming patent risks and weak vaccine sales raise questions on whether investors should hold or trim.
27-Mar-2026 10:02 AM CST - Yahoo Finance Merck Targets Post Keytruda Future With US$6.7b Terns Acquisition Merck (NYSE:MRK) announced a US$6.7b agreement to acquire Terns Pharmaceuticals. The deal adds Terns' lead investigational oral therapy for chronic myeloid leukemia, TERN-701, to Merck's oncology and hematology pipeline.
27-Mar-2026 5:45 AM CST - Yahoo Finance RBC Reiterates Merck (MRK) Outperform, Notes Investor Concerns Over "Modest Premium" Merck & Co., Inc. (NYSE:MRK) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In. On March 25, RBC reiterated an Outperform rating on Merck & Co., Inc. (NYSE:MRK) with a $142 price target.
25-Mar-2026 12:05 PM CST - Seeking Alpha Investors question premium in Merck's $6.7B deal for Terns Pharma - analyst Some investors are questioning the premium Merck ( MRK) is paying in its $6.7 billion acquisition of Tern Pharmaceuticals ( TERN ), according to an RBC analyst. Merck agreed to pay $53 a share for Terns ( TERN ), representing a 6% premium to TERN's closing price on Monday.
25-Mar-2026 11:05 AM CST - Yahoo Finance Merck to acquire Terns Pharmaceuticals for $6.7B Merck & Co Inc (NYSE:MRK, XETRA:6MK) announced on Wednesday that it will acquire US biotech firm Terns Pharmaceuticals (NASDAQ:TERN) for $53 per share in cash, valuing the company at approximately $6.
30-Mar-2026 8:34 AM CST - Yahoo Finance How Investors May Respond To Merck (MRK) WINREVAIR Phase 2 Success In Tough Heart Failure Segment Earlier this week, Merck & Co., Inc. reported detailed Phase 2 CADENCE results showing WINREVAIR (sotatercept-csrk) significantly reduced pulmonary vascular resistance in adults with combined post- and precapillary pulmonary hypertension and heart failure with preserved ejection fraction,
29-Mar-2026 8:05 AM CST - Seeking Alpha Notable healthcare headlines for the week: Merck, Medtronic, and Novartis in focus Under the terms of the merger agreement, Merck, through a subsidiary, will acquire all of the outstanding shares of Terns. As a result of the IPO, the company projects a total dilutive effect of $0.04 per share for Q4 fiscal 2026,
27-Mar-2026 12:08 PM CST - Yahoo Finance Merck Stock Soars 50% in 6 Months: Buy, Hold, or Take Profits? MRK stock has surged over 50% in six months, but looming patent risks and weak vaccine sales raise questions on whether investors should hold or trim.
27-Mar-2026 10:02 AM CST - Yahoo Finance Merck Targets Post Keytruda Future With US$6.7b Terns Acquisition Merck (NYSE:MRK) announced a US$6.7b agreement to acquire Terns Pharmaceuticals. The deal adds Terns' lead investigational oral therapy for chronic myeloid leukemia, TERN-701, to Merck's oncology and hematology pipeline.
27-Mar-2026 5:45 AM CST - Yahoo Finance RBC Reiterates Merck (MRK) Outperform, Notes Investor Concerns Over "Modest Premium" Merck & Co., Inc. (NYSE:MRK) is included among the Dividend Stock Portfolio for Income: 15 Stocks to Invest In. On March 25, RBC reiterated an Outperform rating on Merck & Co., Inc. (NYSE:MRK) with a $142 price target.
25-Mar-2026 12:05 PM CST - Seeking Alpha Investors question premium in Merck's $6.7B deal for Terns Pharma - analyst Some investors are questioning the premium Merck ( MRK) is paying in its $6.7 billion acquisition of Tern Pharmaceuticals ( TERN ), according to an RBC analyst. Merck agreed to pay $53 a share for Terns ( TERN ), representing a 6% premium to TERN's closing price on Monday.
25-Mar-2026 11:05 AM CST - Yahoo Finance Merck to acquire Terns Pharmaceuticals for $6.7B Merck & Co Inc (NYSE:MRK, XETRA:6MK) announced on Wednesday that it will acquire US biotech firm Terns Pharmaceuticals (NASDAQ:TERN) for $53 per share in cash, valuing the company at approximately $6.
